PRKG1 and pulmonary arterial hypertension: Furthermore, the potential for drug repurposing has gained interest, with compounds such as celastrol showing promise in ameliorating hypoxia-induced pulmonary hypertension through modulation of the phosphodiesterase 5 (PDE5)-cGMP-PKG signaling pathway [15].